Literature DB >> 24176288

Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.

Nicola Allen1, Franz Pichler, Tina Wang, Sundip Patel, Sam Salek.   

Abstract

INTRODUCTION: European countries are increasingly utilising health technology assessment (HTA) to inform reimbursement decision-making. However, the current European HTA environment is very diverse, and projects are already underway to initiate a more efficient and aligned HTA practice within Europe. This study aims to identify a non-ranking method for classifying the diversity of European HTA agencies process and the organisational architecture of the national regulatory review to reimbursement systems. METHOD/
RESULTS: Using a previously developed mapping methodology, this research created process maps to describe national processes for regulatory review to reimbursement for 33 European jurisdictions. These process maps enabled the creation of 2 HTA taxonomic sets. The confluence of the two taxonomic sets was subsequently cross-referenced to identify 10 HTA archetype groups. DISCUSSION: HTA is a young, rapidly evolving field and it can be argued that optimal practices for performing HTA are yet to emerge. Therefore, a non-ranking classification approach could objectively characterise and compare the diversity observed in the current European HTA environment.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Keywords:  Comparative analysis; Decision-making; Health care systems; Health technology assessment; Process mapping

Mesh:

Year:  2013        PMID: 24176288     DOI: 10.1016/j.healthpol.2013.09.007

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  8 in total

1.  Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.

Authors:  Nicola Allen; Stuart R Walker; Lawrence Liberti; Chander Sehgal; M Sam Salek
Journal:  CMAJ Open       Date:  2016-11-03

2.  Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

Authors:  László Gulácsi; Alexandru M Rotar; Maciej Niewada; Olga Löblová; Fanni Rencz; Guenka Petrova; Imre Boncz; Niek S Klazinga
Journal:  Eur J Health Econ       Date:  2014-05-16

3.  A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

Authors:  Nicola Allen; Lawrence Liberti; Stuart R Walker; Sam Salek
Journal:  Front Pharmacol       Date:  2017-06-30       Impact factor: 5.810

4.  Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors:  Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal:  Int J Environ Res Public Health       Date:  2020-11-10       Impact factor: 3.390

5.  Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".

Authors:  Unni Gopinathan; Trygve Ottersen; Pascale-Renée Cyr; Kalipso Chalkidou
Journal:  Int J Health Policy Manag       Date:  2021-03-14

6.  From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.

Authors:  Dimitra Panteli; Helene Eckhardt; Alexandra Nolting; Reinhard Busse; Michael Kulig
Journal:  Health Res Policy Syst       Date:  2015-09-25

7.  HTA Implementation Roadmap in Central and Eastern European Countries.

Authors:  Zoltán Kaló; Adrian Gheorghe; Mirjana Huic; Marcell Csanádi; Finn Boerlum Kristensen
Journal:  Health Econ       Date:  2016-01-14       Impact factor: 3.046

8.  Archetype analysis of older adult immunization decision-making and implementation in 34 countries.

Authors:  Lois Privor-Dumm; Prarthana Vasudevan; Kana Kobayashi; Jaya Gupta
Journal:  Vaccine       Date:  2020-04-16       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.